B2M overexpression is correlated with a poor prognosis in several human cancers, including pancreatic ductal adenocarcinoma[41–43] and it has been considered as a potential target for cancer therapy.[41,42] Consistently, we found that CXCL10, CD44, B2M, XRCC5, PTPN11, and RPL11 were upregulated in the LA-NPC tumors with metastasis compared with tumors without metastasis, and genes CD44, B2M, PTPN11, and RPL11 were associated with the DFS in NPC patients in the GSE102349 dataset. The gene discussed is XRCC5; the disease is pancreatic ductal adenocarcinoma.